Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib

Jorge J. Castillo, Jithma P. Abeykoon, Joshua N. Gustine, Saurabh Zanwar, Kirsten Meid, Catherine A. Flynn, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nickolas Tsakmaklis, Rebecca King, Guang Yang, Zachary R. Hunter, Ranjana H. Advani, Maria Lia Palomba, Stephen M. Ansell, Morie A. Gertz, Prashant Kapoor and Steven P. Treon

Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib

BJH First published online 18 November 2020 doi: 10.1111/bjh.17225